NuVasive to Sponsor and Participate at the Cervical Spine Research Society 50th Annual Meeting
SAN DIEGO, Nov. 14, 2022 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Cervical Spine Research Society (CSRS) as a diamond sponsor and will attend the CSRS 50th Annual Meeting held November 16 to 19 in San Diego.
“The recent launch of our leading posterior cervical fusion solution, Reline Cervical, and our annual meeting sponsorship of a preeminent cervical society, CSRS, underscores our shared belief in further advancing cervical technology,” said Chris Barry, chief executive officer at NuVasive. “We look forward to showcasing our comprehensive, procedurally integrated C360 portfolio, and its initial step toward intelligent surgery with full Pulse compatibility.”
NuVasive will host two workshops on Thursday, November 17 in room Hillcrest CD. From 6:30 to 7:15 a.m. PT, a hands-on workshop, TDR: What are you waiting for? Fantasy vs. reality, featuring Dr. Ali Mesiwala, DISC Sports and Spine Center, and Dr. Rory Murphy, Barrow Neurological Institute. From 11:30 a.m. to 12:30 p.m. PT, an industry lunch workshop, Approaching cervicothoracic kyphotic deformities—anterior, posterior and 360, featuring Dr. Praveen Mummaneni, UCSF Health, Dr. Rick Sasso, Indiana Spine Hospital, and Dr. Todd Albert, Hospital for Special Surgery.
NuVasive booth #105/204 will feature the Company’s full C360™ portfolio, made up of best-in-class access instrumentation, implants, biologic materials, and enabling technologies within Pulse® for the anterior and posterior cervical spine.
About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company’s less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company’s comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals, and patients. For more information, please visit www.nuvasive.com.
Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products, the Company’s ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
SOURCE NuVasive, Inc.
